AT
ATX.AU Amplia Therapeutics Ltd
- Market cap
- AUD 43.1M
- P/E
- -
- P/B
- 1.09x
- ROE
- -19.5%
- Dividend yield
- -
- Fundamental score
- 2.0/5
Ratios use the latest price and the fiscal year ending Mar 2026.
Is ATX.AU undervalued?
Graham numberThe Graham number of Amplia Therapeutics Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Amplia Therapeutics Ltd fundamental analysis
9 of 21 checks passedROE 0/2
Low return on equity (-19.5%), below 10%.
ROA 1/1
Return on assets (-18.6%) is above the industry median (-51.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (23.3%) is above the industry median (-5.3%).
Revenue Growth 0/2
Revenue did not grow over the past 3 years or is not reported.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (0.9%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Cash Runway 2/2
Cash covers 3.2 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (1.1x) is below the industry median (4.4x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Amplia Therapeutics Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Amplia Therapeutics Ltd
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2b clinical trial for pancreatic cancer; and treatment of ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immuno…
Full company profileAmplia Therapeutics Ltd financial statements
Amplia Therapeutics Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 1.80M | 580K | 50.5K | 34.2K | 1.53M | 1.98M | 1.19M | 4.45M | 3.78M | - |
| Gross Profit | 1.76M | 560K | 48.9K | 33.4K | 1.53M | 1.98M | 1.12M | 4.01M | 3.57M | -92.1K |
| Operating Income | -8.97M | -4.83M | -1.93M | -2.26M | -3.88M | -3.64M | -7.48M | -4.42M | -6.52M | -13.2M |
| EBITDA | -7.10M | -4.30M | -1.92M | -2.25M | -3.81M | -3.64M | -7.26M | -4.48M | -6.71M | -13.1M |
| Net Income | -7.08M | -4.30M | -1.87M | -2.22M | -2.28M | -3.64M | -6.24M | -4.50M | -6.57M | -7.71M |
| EPS | -0.30 | -0.17 | -0.04 | -0.04 | -0.02 | -0.03 | -0.03 | -0.02 | -0.02 | -0.02 |
| Balance Sheet | ||||||||||
| Total Assets | 7.54M | 2.64M | 9.19M | 9.12M | 10.9M | 24.5M | 18.7M | 14.8M | 22.9M | 41.4M |
| Total Liabilities | 908K | 279K | 527K | 511K | 539K | 2.64M | 2.85M | 3.43M | 1.91M | 1.97M |
| Shareholders' Equity | 6.63M | 2.36M | 8.66M | 8.61M | 10.3M | 21.8M | 15.8M | 11.4M | 21.0M | 39.5M |
| Cash & Short-term Investments | 5.76M | 2.23M | 1.24M | 1.11M | 1.85M | 14.6M | 9.26M | 3.39M | 10.9M | 27.9M |
| Total Debt | 10.3K | 10.6K | 10.6K | - | 2.10M | 4.28M | 2.27M | 1.59M | 13.9K | 341K |
| Cash Flow | ||||||||||
| Operating Cash Flow | -6.16M | -3.55M | -987K | -2.09M | -2.92M | -4.40M | -5.29M | -5.13M | -6.89M | -8.73M |
| Capital Expenditure | 46.5K | 4.42K | 3.19K | 5.00K | 5.35K | 14.4K | 17.6K | 2.23K | 2.07K | 33.3K |
| Free Cash Flow | -6.21M | -3.55M | -991K | -2.09M | -2.92M | -4.42M | -5.31M | -5.13M | -6.89M | -8.77M |
| Ratios | ||||||||||
| ROE | -106.7% | -181.8% | -21.6% | -25.8% | -22.1% | -16.7% | -39.4% | -39.4% | -31.3% | -19.5% |
| ROA | -93.9% | -162.6% | -20.3% | -24.3% | -21.0% | -14.9% | -33.4% | -30.3% | -28.7% | -18.6% |
| Net Profit Margin | -393.5% | -740.6% | -3,704.8% | -6,484.6% | -148.8% | -183.7% | -524.8% | -101.1% | -173.7% | - |
| Debt to Equity | 0.00x | 0.00x | 0.00x | - | 0.20x | 0.20x | 0.14x | 0.14x | 0.00x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Amplia Therapeutics Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | NZD 16.0M | 0.11 | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:10 on Apr 30, 2018.
Who owns Amplia Therapeutics Ltd
- Insiders 9.56%
- Institutions 23.05%
- Public & others 67.39%
- Shares outstanding 513M
- Free float 414M
Amplia Therapeutics Ltd company profile
- Company name
- Amplia Therapeutics Ltd
- Ticker
- ATX.AU
- ISIN
- AU0000023822
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- March
- Address
- 90 William Street, Melbourne, VIC, Australia, 3000
- Phone
- 61 3 9123 1140
- Website
- ampliatx.com
About Amplia Therapeutics Ltd
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2b clinical trial for pancreatic cancer; and treatment of ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Amplia Therapeutics Ltd management
5- Dr. Christopher J. Burns B.Sc., BSc(Hons), Ph.D.CEO, MD & Director · born 1965
- Mr. Hamish George B.Com., C.A.Chief Financial Officer
- Ms. Rhiannon Jones B.Sc., Ph.D.Chief Operating Officer
- Dr. Jason Lickliter MBBSChief Medical Officer
- Mr. Andrew John Cooke FAICS, FCIS, FGIA, L.L.B., MAICDCompany Secretary · born 1960